GlassScriptPhysician profile
Debra J Connell-Dent
NPI 1558904508
$1,822.76
in general payments reported to CMS, 2019-2025
27 companies · $178 in 2025
The $178 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2023: $791 · 2024: $732 · 2025: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $231.52 | 2023-2025 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $191.71 | 2023-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $157.73 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Exact Sciences Corporation | $133.36 | 2023-2024 | Cologuard Collection Kit |
| Novo Nordisk INC | $119.91 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Medtronic, INC. | $104.93 | 2023-2025 | Intellis Adaptivestim, Inceptiv |
| Neurocrine Biosciences, INC. | $104.39 | 2024 | Ingrezza |
| Novartis Pharmaceuticals Corporation | $97.05 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.98 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.72 | 2023-2025 | Xifaxan |
| Ironwood Pharmaceuticals, INC | $75.66 | 2023-2024 | Linzess |
| Orexo US, INC. | $63.66 | 2021 | |
| Pfizer INC. | $59.10 | 2024-2025 | |
| Alkermes, INC. | $58.80 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $33.12 | 2023-2024 | Farxiga, Fasenra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $29.56 | 2024-2025 | Zenpep |
| Abbvie INC. | $28.07 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $26.88 | 2023 | |
| Merck Sharp & Dohme LLC | $22.92 | 2023 | Verquvo, Belsomra |
| Edwards Lifesciences Corporation | $21.46 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Phadia US INC. | $18.41 | 2023 | Immunocap |
| Idorsia Pharmaceuticals US INC | $15.36 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $14.99 | 2024 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $13.95 | 2023 | |
| Nestle Healthcare Nutrition INC. | $13.93 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $13.40 | 2023 | Rexulti |
| Ardelyx, INC. | $13.19 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Connell-Dent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.